UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 167

Sortiert nach

Platform Trials — Beware the Noncomparable Control Group

The New England journal of medicine, 2021-04, Vol.384 (16), p.1572-1573

2021

Link zum Volltext

Verfügbarkeit prüfen

Outcome-Adaptive Randomization: Is It Useful?

Journal of clinical oncology, 2011-02, Vol.29 (6), p.771-776

2011

Link zum Volltext

Verfügbarkeit prüfen

Time trends with response-adaptive randomization: The inevitability of inefficiency

Clinical trials (London, England), 2022-04, Vol.19 (2), p.158-161

2022

Link zum Volltext

Verfügbarkeit prüfen

Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?

Clinical cancer research, 2018-05, Vol.24 (10), p.2239-2240

2018

Link zum Volltext

Verfügbarkeit prüfen

The Cross-Validated Adaptive Signature Design

Clinical cancer research, 2010-01, Vol.16 (2), p.691-698

2010

Link zum Volltext

Verfügbarkeit prüfen

Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients

Clinical cancer research, 2005-11, Vol.11 (21), p.7872-7878

2005

Link zum Volltext

Verfügbarkeit prüfen

Are restricted mean survival time methods especially useful for noninferiority trials?

Clinical trials (London, England), 2021-04, Vol.18 (2), p.188-196

2021

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies

Journal of clinical oncology, 2011-06, Vol.29 (17), p.2439-2442

2011

Link zum Volltext

Verfügbarkeit prüfen

Reply to Quartagno et al

Clinical trials (London, England), 2021-12, Vol.18 (6), p.746-746

2021

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Trial Designs With Biomarkers

Journal of clinical oncology, 2012-09, Vol.30 (26), p.3304-3309

2012

Link zum Volltext

Verfügbarkeit prüfen

Noninferiority trials with nonadherence to the assigned randomized treatment

Clinical trials (London, England), 2019-12, Vol.16 (6), p.673-681

2019

Link zum Volltext

Verfügbarkeit prüfen

Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials

Journal of clinical oncology, 2005-10, Vol.23 (28), p.7199-7206

2005

Link zum Volltext

Verfügbarkeit prüfen

Targeting epidermal growth factor receptor—are we missing the mark?

The Lancet (British edition), 2003-07, Vol.362 (9377), p.62-64

2003

Link zum Volltext

Verfügbarkeit prüfen

Multi-Arm Clinical Trials of New Agents: Some Design Considerations

Clinical cancer research, 2008-07, Vol.14 (14), p.4368-4371

2008

Link zum Volltext

Verfügbarkeit prüfen

Design Issues in Randomized Phase II/III Trials

Journal of clinical oncology, 2012-02, Vol.30 (6), p.667-671

2012

Link zum Volltext

Verfügbarkeit prüfen

Adaptive randomization versus interim monitoring

Journal of clinical oncology, 2013-03, Vol.31 (7), p.969-970

2013

Link zum Volltext

Verfügbarkeit prüfen

Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?

Journal of clinical oncology, 2008-08, Vol.26 (22), p.3791-3796

2008

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Randomized Discontinuation Design

Journal of clinical oncology, 2005-08, Vol.23 (22), p.5094-5098

2005

Link zum Volltext

Verfügbarkeit prüfen

Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2007-03, Vol.25 (7), p.760-766

2007

Link zum Volltext

Verfügbarkeit prüfen

Accrual Experience of National Cancer Institute Cooperative Group Phase III Trials Activated From 2000 to 2007

Journal of clinical oncology, 2010-12, Vol.28 (35), p.5197-5201

2010

Link zum Volltext

Verfügbarkeit prüfen

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

Blood cancer journal (New York), 2022-06, Vol.12 (6), p.98-98, Article 98

2022

Link zum Volltext

Verfügbarkeit prüfen

Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials

The cancer journal (Sudbury, Mass.), 2019-07, Vol.25 (4), p.254

2019

Link zum Volltext

Verfügbarkeit prüfen

Marker Sequential Test (MaST) design

Clinical trials (London, England), 2014-02, Vol.11 (1), p.19-27

2014

Link zum Volltext

Verfügbarkeit prüfen

NCI―RTOG Translational Program Strategic Guidelines for the Early-Stage Development of Radiosensitizers

JNCI : Journal of the National Cancer Institute, 2013-01, Vol.105 (1), p.11-24

2013

Link zum Volltext

Verfügbarkeit prüfen

Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005

Journal of clinical oncology, 2009-04, Vol.27 (10), p.1712-1721

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 167

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(153)
Mit Volltextzugriff
(158)

Publikationsform

Artikel
(157)
Buchkapitel
(10)

Sprache

Englisch
(167)
Japanisch
(22)

Erscheinungsjahr

n.n

Thema

Science & Technology
(125)
Life Sciences & Biomedicine
(121)
Humans
(113)
Oncology
(72)
Research Design
(51)
Clinical Trials
(39)
Medical Sciences
(35)
Biological And Medical Sciences
(33)
Medicine, Research & Experimental
(27)
Research & Experimental Medicine
(27)
Mathematics
(26)
Randomized Controlled Trials As Topic
(26)
Physical Sciences
(24)
Statistics & Probability
(24)
Treatment Outcome
(24)
Neoplasms - Drug Therapy
(22)
Tumors
(22)
Data Interpretation, Statistical
(21)
Sample Size
(21)
Mathematical & Computational Biology
(20)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(38)
Jnci : Journal Of The National Cancer Institute
(28)
Clinical Trials
(20)
Statistics In Medicine
(11)
Clinical Cancer Research
(9)
Biometrics
(6)
Biometrical Journal
(3)
Cancer
(3)
Controlled Clinical Trials
(3)
The Lancet
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Platform Trials — Beware the Noncomparable Control Group

Outcome-Adaptive Randomization: Is It Useful?

Time trends with response-adaptive randomization: The inevitability of inefficiency

Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?

The Cross-Validated Adaptive Signature Design

Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients

Are restricted mean survival time methods especially useful for noninferiority trials?

Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies

Reply to Quartagno et al

Randomized Phase II Trial Designs With Biomarkers

Noninferiority trials with nonadherence to the assigned randomized treatment

Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials

Targeting epidermal growth factor receptor—are we missing the mark?

Multi-Arm Clinical Trials of New Agents: Some Design Considerations

Design Issues in Randomized Phase II/III Trials

Adaptive randomization versus interim monitoring

Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?

Evaluation of Randomized Discontinuation Design

Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer

Accrual Experience of National Cancer Institute Cooperative Group Phase III Trials Activated From 2000 to 2007

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials

Marker Sequential Test (MaST) design

NCI―RTOG Translational Program Strategic Guidelines for the Early-Stage Development of Radiosensitizers

Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005

Suchergebnisse filtern